If approved, Awiqli would become the first once-weekly basal insulin available in the United States for adults with Type 2 diabetes. Novo Nordisk has resubmitted its biologics license application (BLA ...
Indian drugmakers Eris Lifesciences, Wockhardt and Lupin are prepping to cash in when Danish company Novo Nordisk bows out of the human insulin pen market by the end of this year and creates an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback